Prostate cancer: emerging pharmacotherapeutic modalities

Prostate cancer is the most common cancer in the world due to factors like old age, family history, ethnicity, diet and some elements exposure, with lot of controversies regarding prevention of prostate cancer. Though the exact pathogenesis is not clear, epidemiological evidence supports a relationship between prostate cancer and hormone levels. In this review article we are focusing on the advances in different pharmacotherapeutic modalities i.e. Chemoprevention, Prostate-Specific Antigen, Hormone Therapy, Anti-Inflammatory Drugs, SERM, Vaccines, Cryotherapy, Watchful Waiting, Radiotherapy and Androgen Deprivation Therapy etc. and new possibilities with strategies to provide maximal benefits while effectively balancing risks for the prostate cancer treatment. [Int J Basic Clin Pharmacol 2013; 2(3.000): 247-251]